Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Ezetimibe

Ezetimibe Am J Cardiovasc Drugs 2003; 3 (1): 77-78 GUEST COMMENTARIES 1175-3277/03/0001-0077/$30.00/0 © Adis International Limited. All rights reserved. 3% as compared with controls. It is well tolerated, adverse event rates being similar to those with placebo controls. A Viewpoint by Tatu A. Miettinen LDL-C lowering with ezetimibe was associated with a 54% Department of Medicine, University of Helsinki, Helsinki, Finland reduction of cholesterol absorption and subsequently with a [3] marked increase of cholesterol synthesis. This latter effect can Plasma cholesterol levels can be reduced by inhibiting choles- be prevented by coadministration of ezetimibe with statins, terol synthesis with statins, preventing bile acid absorption with bile acid sequestrants or inhibiting cholesterol absorption. Cho- which inhibit cholesterol synthesis. The synergistic and well-tol- lesterol absorption can be inhibited in the long term with contin- erated effects of the two drugs can normalise LDL-C levels even [1] ued consumption of sitostanol ester-containing margarine at relatively low doses of statins. which lowers LDL-C by up to 20%, a magnitude usually obtained Many patients with mild hypercholesterolemia respond to with cholesterol absorption inhibitors. ezetimibe monotherapy but patients with more severe disease, Ezetimibe, an azetidinone derivative, is a new inhibitor of cho- and those unable to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Ezetimibe

Download PDF
1 page

Ezetimibe

Abstract

Am J Cardiovasc Drugs 2003; 3 (1): 77-78 GUEST COMMENTARIES 1175-3277/03/0001-0077/$30.00/0 © Adis International Limited. All rights reserved. 3% as compared with controls. It is well tolerated, adverse event rates being similar to those with placebo controls. A Viewpoint by Tatu A. Miettinen LDL-C lowering with ezetimibe was associated with a 54% Department of Medicine, University of Helsinki, Helsinki, Finland reduction of cholesterol absorption and subsequently with a [3] marked...
Loading next page...
 
/lp/springer-journals/ezetimibe-OCeOAI6oI7

References (3)

Publisher
Springer Journals
Copyright
Copyright © 2003 by Adis International Limited
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
DOI
10.2165/00129784-200303010-00010
Publisher site
See Article on Publisher Site

Abstract

Am J Cardiovasc Drugs 2003; 3 (1): 77-78 GUEST COMMENTARIES 1175-3277/03/0001-0077/$30.00/0 © Adis International Limited. All rights reserved. 3% as compared with controls. It is well tolerated, adverse event rates being similar to those with placebo controls. A Viewpoint by Tatu A. Miettinen LDL-C lowering with ezetimibe was associated with a 54% Department of Medicine, University of Helsinki, Helsinki, Finland reduction of cholesterol absorption and subsequently with a [3] marked increase of cholesterol synthesis. This latter effect can Plasma cholesterol levels can be reduced by inhibiting choles- be prevented by coadministration of ezetimibe with statins, terol synthesis with statins, preventing bile acid absorption with bile acid sequestrants or inhibiting cholesterol absorption. Cho- which inhibit cholesterol synthesis. The synergistic and well-tol- lesterol absorption can be inhibited in the long term with contin- erated effects of the two drugs can normalise LDL-C levels even [1] ued consumption of sitostanol ester-containing margarine at relatively low doses of statins. which lowers LDL-C by up to 20%, a magnitude usually obtained Many patients with mild hypercholesterolemia respond to with cholesterol absorption inhibitors. ezetimibe monotherapy but patients with more severe disease, Ezetimibe, an azetidinone derivative, is a new inhibitor of cho- and those unable to

Journal

American Journal of Cardiovascular Drugs – Springer Journals

Published: Aug 20, 2012

There are no references for this article.